Primary Tumor Resection in Metastatic Colorectal Cancer

Resection of the primary tumour in patients presenting with metastatic colorectal cancer has long been the subject of clinical and surgical debate. On the one hand, removal of the primary lesion can prevent complications such as obstruction, bleeding or perforation, and may improve the delivery and efficacy of systemic therapies. On the other hand, surgery delays the initiation of chemotherapy, carries operative risk and may not confer a survival advantage in asymptomatic individuals. Retrospective analyses have frequently suggested a benefit in overall survival for patients undergoing resection, yet prospective trials and meta-analyses have yielded mixed results. Current practice demands a nuanced appraisal of patient fitness, tumour burden, symptom profile and molecular markers to guide a multidisciplinary decision. In an era of targeted agents and immunotherapy, the role of primary resection continues to evolve as systemic regimens become more effective and as prognostic stratification allows greater individualisation of care.

Research from Nature Portfolio

Instrumental variable analysis of a large national cancer registry has demonstrated that primary tumour resection is associated with improved overall and cancer-specific survival in unresectable stage IV disease. By accounting for selection biases, this study provides strong evidence that surgical removal of the primary lesion contributes independently to long-term outcomes.

A pooled analysis of trials investigating bevacizumab in metastatic colorectal cancer revealed that the survival benefit of antiangiogenic therapy is most pronounced in patients who have undergone primary tumour resection. Those with resected lesions experienced significantly longer progression-free and overall survival compared with patients treated without surgery, suggesting an interaction between the tumour microenvironment and systemic anti-VEGF therapy.

Primary Tumor Resection in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in primary tumor resection in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Metastatic colorectal cancer: Colorectal carcinoma that has spread beyond the primary site to distant organs, most commonly the liver or lungs.

Primary tumour resection (PTR): Surgical removal of the original colorectal tumour in the setting of incurable metastatic disease.

Synchronous metastasis: Metastatic deposits identified at the time of initial colorectal cancer diagnosis.

Cancer-specific survival: The interval from diagnosis or treatment to death attributable directly to colorectal cancer, excluding other causes.

References

1. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Annals of Oncology (2024).
2. The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. Cancers (2020).
3. Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis. Scientific Reports (2015).
4. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. Scientific Reports (2019).